Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 6/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473504 | 0.84 | CYP2C19 (0.53) | ALDH1A1CYP3A4CYP2C19HIF1AKDM4E | |
| SCHEMBL6631546 | 0.83 | BLM (0.56) | BLMESR1ESR2CA2CAMK2A | |
| SCHEMBL17590423 | 0.83 | TBXA2R (0.54) | CYP3A4CYP2C19TSHRTBXA2R | |
| SCHEMBL450334 | 0.83 | TBXA2R (0.53) | BLMALDH1A1CYP2C19HIF1AMEN1 | |
| SCHEMBL6803878 | 0.80 | ESR1 (0.50) | BLMESR1ESR2CA2ALDH1A1 | |
| SCHEMBL6809716 | 0.78 | ESR1 (0.47) | BLMESR1ESR2CA2MEN1 | |
| SCHEMBL6800310 | 0.77 | FFAR1 (0.57) | CYP2C19HIF1AMEN1KMT2AKDM4E | |
| SCHEMBL11596247 | 0.76 | BLM (0.67) | BLMESR1ESR2CA2CAMK2A | |
| SCHEMBL5004593 | 0.76 | BLM (0.67) | BLMESR1ESR2CA2CAMK2A | |
| Eucomic Acid SCHEMBL23355983 | 0.76 | BLM (0.51) | BLMESR1ESR2CA2CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | BLM 3951/4885ESR1 3570/4885ESR2 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.